CRISPR Editing Heads Off Disease in Mouse Livers

Separate proof-of-concept studies report success against two inherited diseases.

Written byShawna Williams
| 2 min read
a white mouse on a black background

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK, SIDSNAPPER

Two studies published yesterday (October 9) in Nature Medicine report success using modified CRISPR-Cas9 gene editing to prevent or cure two inherited diseases in mice. In one study, researchers corrected the gene mutation that causes phenylketonuria (PKU) in the livers of adult mice; in the other, editing short-circuited a condition similar to the human disease HT1 in the livers of fetal mice.

In the PKU study, carried out at ETH Zurich in Switzerland, researchers bundled a CRISPR-Cas9 system plus the enzyme cytidine deaminase into an adeno-associated viral vector and injected it into the livers of mice with defective genes for phenylalanine hydroxylase. (A lack of functional phenylalanine hydroxylase causes a toxic buildup of phenylalanine in patients with PKU unless they’re diagnosed soon after birth and put on a special diet.) The gene-editing homed in on and changed a single base pair in the genomes of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies